CD274 and metastatic melanoma: In a phase III trial of nivolumab—an anti-PD-1 antibody—metastatic melanoma patients with PD-L1 positive tumors showed an ORR of 52.7% and those with PD-L1 indeterminate or negative tumors demonstrated an ORR of 33.1% [68].